Table 2 Incidences and grades of cetuximab-induced hypersensitivity infusion reactions (CI-IRs) in each area with different Lyme disease risks
Areas | Estimated mean annual regional incidence rates of Lyme diseasea(per 100 000 inhabitants) | Incidences of CI-IRs | |||||||
|---|---|---|---|---|---|---|---|---|---|
Grade 1, N (%) | Grade 2, N (%) | Grade 3, N (%) | Grade 4, N (%) | Grade 5, N (%) | Low gradeb, N (%) | Severe gradec, N (%) | Any grades, N (%) | ||
High-risk area Limoges (N = 266) | > 150 | 3 (1.1) | 10 (3.8) | 14 (5.3) | 8 (3.0) | 0 | 13 (4.9) | 22 (8.3) | 35 (13.2) |
Medium-risk area Nancy (N = 467) | 50–100 | 7 (1.5) | 10 (2.1) | 14 (3.0) | 2 (0.4) | 0 | 17 (3.6) | 16 (3.4) | 33 (7.1) |
Low-risk area Reims (N = 407) | 20–50 | 4 (1.0) | 7 (1.7) | 14 (3.4) | 8 (2.0) | 0 | 11 (2.7) | 22 (5.4) | 33 (8.1) |
Very-low-risk area Amiens (N = 252) | 5–20 | 4 (1.6) | 4 (1.6) | 5 (2.0) | 3 (1.2) | 0 | 8 (3.2) | 8 (3.2) | 16 (6.4) |
Overall study population (N = 1392) | 18 (1.3) | 31 (2.2) | 47 (3.4) | 21 (1.5) | 0 | 49 (3.5) | 68 (4.9) | 117 (8.4) | |